US2016264661A1PendingUtilityA1
Anti-il-12/il-23 antibodies
Assignee: TEVA PHARMACEUTICALS AUSTRALIA PTY LTDPriority: Aug 14, 2008Filed: Apr 22, 2016Published: Sep 15, 2016
Est. expiryAug 14, 2028(~2.1 yrs left)· nominal 20-yr term from priority
Inventors:Adam ClarkeAnthony G. DoylePhilip Anthony JenningsLynn Dorothy PoultonHoi Yi WaiAndrew James PowGeorge Kopsidas
A61P 37/02A61P 5/14A61P 9/10A61P 41/00A61P 37/08A61P 3/08A61P 9/00A61P 7/00A61P 37/06A61P 25/04A61P 25/00A61P 29/00A61P 25/28A61P 27/00A61P 35/00A61P 27/02A61P 31/00A61P 3/00A61P 31/04A61P 1/16A61P 11/00A61P 1/04A61P 1/02A61P 1/00A61P 19/10A61P 17/14A61P 19/02A61P 17/06A61P 19/08A61P 19/04A61P 13/12A61P 17/00A61K 2039/505A61K 39/395C07K 16/244C07K 2317/622C07K 2317/92C07K 2317/24C07K 2317/565C07K 2317/56C07K 2317/34C07K 14/5434C07K 2317/567C07K 2317/76
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An antibody which comprises three heavy chain CDR sequences selected from:
(SEQ ID NO: 371)
HCDR1 DYYX 1 H,
wherein;
X 1 = M or L;
(SEQ ID NO: 372)
HCDR2 WIDPENGDTEX 2 APKFQG,
wherein;
X 2 = Y, H, or S;
(SEQ ID NO: 373)
HCDR3 X 3 KELRYFDV,
wherein;
X 3 = C, A, N, D, E, Q, G, H, I, L, P or V.
and three light chain CDR sequences selected from:
(SEQ ID NO: 374)
LCDR1 RAX 4 X 5 SISINLH,
wherein;
X 4 = S or P;
X 5 = Q or R;
(SEQ ID NO: 375)
LCDR2 FAX 6 QSX 7 S,
wherein;
X 6 = S or R;
X 7 = I or T;
(SEQ ID NO: 376)
LCDR3 QQSNSX 8 PLT,
wherein;
X 8 = W or F.
2 . An antibody as claimed in claim 1 in which the antibody further comprises a human heavy chain acceptor framework sequence selected from the group consisting of SEQ ID NO: 202, SEQ ID NO: 205, SEQ ID NO: 208, SEQ ID NO: 203, SEQ ID NO: 206, SEQ ID NO: 209, SEQ ID NO: 204 and SEQ ID NO: 207.
3 . An antibody as claimed in claim 1 in which the antibody further comprises a human light chain acceptor framework sequence selected from the group consisting of SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 216, SEQ ID NO: 211, SEQ ID NO: 214, SEQ ID NO: 212 and SEQ ID NO: 215.
4 . An antibody as claimed in claim 1 in which the antibody comprises an immunoglobulin heavy chain variable region selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 62, SEQ ID NO: 114, SEQ ID NO: 142, SEQ ID NO: 28, SEQ ID NO: 87, SEQ ID NO: 115, SEQ ID NO: 143, SEQ ID NO: 29, SEQ ID NO: 88, SEQ ID NO: 116, SEQ ID NO: 144, SEQ ID NO: 30, SEQ ID NO: 90, SEQ ID NO: 117, SEQ ID NO: 145, SEQ ID NO: 31, SEQ ID NO: 91, SEQ ID NO: 118, SEQ ID NO: 146, SEQ ID NO: 33, SEQ ID NO: 92, SEQ ID NO: 119, SEQ ID NO: 147, SEQ ID NO: 34, SEQ ID NO: 93, SEQ ID NO: 120, SEQ ID NO: 148, SEQ ID NO: 35, SEQ ID NO: 94, SEQ ID NO: 122, SEQ ID NO: 149, SEQ ID NO: 36, SEQ ID NO: 95, SEQ ID NO: 124, SEQ ID NO: 150, SEQ ID NO: 38, SEQ ID NO: 96, SEQ ID NO: 125, SEQ ID NO: 151, SEQ ID NO: 39, SEQ ID NO: 97, SEQ ID NO: 126, SEQ ID NO: 152, SEQ ID NO: 40, SEQ ID NO: 99, SEQ ID NO: 127, SEQ ID NO: 153, SEQ ID NO: 41, SEQ ID NO: 100, SEQ ID NO: 128, SEQ ID NO: 154, SEQ ID NO: 42, SEQ ID NO: 101, SEQ ID NO: 129, SEQ ID NO: 155, SEQ ID NO: 43, SEQ ID NO: 102, SEQ ID NO: 130, SEQ ID NO: 156, SEQ ID NO: 44, SEQ ID NO: 103, SEQ ID NO: 131, SEQ ID NO: 157, SEQ ID NO: 45, SEQ ID NO: 104, SEQ ID NO: 132, SEQ ID NO: 158, SEQ ID NO: 53, SEQ ID NO: 105, SEQ ID NO: 133, SEQ ID NO: 159, SEQ ID NO: 54, SEQ ID NO: 106, SEQ ID NO: 134, SEQ ID NO: 160, SEQ ID NO: 55, SEQ ID NO: 107, SEQ ID NO: 135, SEQ ID NO: 161, SEQ ID NO: 56, SEQ ID NO: 108, SEQ ID NO: 136, SEQ ID NO: 162, SEQ ID NO: 57, SEQ ID NO: 109, SEQ ID NO: 137, SEQ ID NO: 163, SEQ ID NO: 58, SEQ ID NO: 110, SEQ ID NO: 138, SEQ ID NO: 164, SEQ ID NO: 59, SEQ ID NO: 111, SEQ ID NO: 139, SEQ ID NO: 165, SEQ ID NO: 60, SEQ ID NO: 112, SEQ ID NO: 140, SEQ ID NO: 166, SEQ ID NO: 61, SEQ ID NO: 113, SEQ ID NO: 141 and SEQ ID NO: 167.
5 . An antibody as claimed in claim 1 in which the antibody comprises an immunoglobulin light chain variable region selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 169, SEQ ID NO: 181, SEQ ID NO: 193, SEQ ID NO: 32, SEQ ID NO: 170, SEQ ID NO: 182, SEQ ID NO: 194, SEQ ID NO: 37, SEQ ID NO: 171, SEQ ID NO: 183, SEQ ID NO: 195, SEQ ID NO: 42, SEQ ID NO: 172, SEQ ID NO: 184, SEQ ID NO: 196, SEQ ID NO: 46, SEQ ID NO: 173, SEQ ID NO: 185, SEQ ID NO: 197, SEQ ID NO: 47, SEQ ID NO: 174, SEQ ID NO: 186, SEQ ID NO: 198, SEQ ID NO: 48, SEQ ID NO: 175, SEQ ID NO: 187, SEQ ID NO: 199, SEQ ID NO: 49, SEQ ID NO: 176, SEQ ID NO: 188, SEQ ID NO: 200, SEQ ID NO: 50, SEQ ID NO: 177, SEQ ID NO: 189, SEQ ID NO: 201, SEQ ID NO: 51, SEQ ID NO: 178, SEQ ID NO: 190, SEQ ID NO: 52, SEQ ID NO: 179 and SEQ ID NO: 192
6 . An antibody as claimed in claim 5 in which the antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and wherein the antibody inhibits the binding of human IL-12 to human IL-12Rβ2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12Rβ1.
7 . An antibody as claimed in claim 1 in which the antibody comprises two immunoglobulin variable regions, wherein the said two immunoglobulin variable regions are selected from a group consisting of:
SEQ ID NO: 6 & SEQ ID NO: 7
SEQ ID NO: 6 & SEQ ID NO: 169
SEQ ID NO: 28 & SEQ ID NO: 179
SEQ ID NO: 29 & SEQ ID NO: 179
SEQ ID NO: 30 & SEQ ID NO: 179
SEQ ID NO: 31 & SEQ ID NO: 32
SEQ ID NO: 33 & SEQ ID NO: 179
SEQ ID NO: 34 & SEQ ID NO: 51
SEQ ID NO: 34 & SEQ ID NO: 47
SEQ ID NO: 35 & SEQ ID NO: 179
SEQ ID NO: 36 & SEQ ID NO: 37
SEQ ID NO: 38 & SEQ ID NO: 179
SEQ ID NO: 38 & SEQ ID NO: 51
SEQ ID NO: 38 & SEQ ID NO: 32
SEQ ID NO: 38 & SEQ ID NO: 47
SEQ ID NO: 38 & SEQ ID NO: 52
SEQ ID NO: 39 & SEQ ID NO: 179
SEQ ID NO: 40 & SEQ ID NO: 179
SEQ ID NO: 41 & SEQ ID NO: 42
SEQ ID NO: 43 & SEQ ID NO: 179
SEQ ID NO: 44 & SEQ ID NO: 179
SEQ ID NO: 44 & SEQ ID NO: 51
SEQ ID NO: 44 & SEQ ID NO: 32
SEQ ID NO: 44 & SEQ ID NO: 47
SEQ ID NO: 44 & SEQ ID NO: 52
SEQ ID NO: 45 & SEQ ID NO: 179
SEQ ID NO: 45 & SEQ ID NO: 179
SEQ ID NO: 53 & SEQ ID NO: 41
SEQ ID NO: 54 & SEQ ID NO: 179
SEQ ID NO: 55 & SEQ ID NO: 179
SEQ ID NO: 56 & SEQ ID NO: 179
SEQ ID NO: 57 & SEQ ID NO: 179
SEQ ID NO: 58 & SEQ ID NO: 42
SEQ ID NO: 59 & SEQ ID NO: 179
SEQ ID NO: 60 & SEQ ID NO: 179
SEQ ID NO: 61 & SEQ ID NO: 42
SEQ ID NO: 62 & SEQ ID NO: 42
SEQ ID NO: 87 & SEQ ID NO: 7
SEQ ID NO: 88 & SEQ ID NO: 7
SEQ ID NO: 90 & SEQ ID NO: 7
SEQ ID NO: 91 & SEQ ID NO: 7
SEQ ID NO: 92 & SEQ ID NO: 7
SEQ ID NO: 93 & SEQ ID NO: 7
SEQ ID NO: 94 & SEQ ID NO: 7
SEQ ID NO: 95 & SEQ ID NO: 7
SEQ ID NO: 96 & SEQ ID NO: 7
SEQ ID NO: 97 & SEQ ID NO: 7
SEQ ID NO: 99 & SEQ ID NO: 7
SEQ ID NO: 100 & SEQ ID NO: 7
SEQ ID NO: 101 & SEQ ID NO: 7
SEQ ID NO: 102 & SEQ ID NO: 7
SEQ ID NO: 103 & SEQ ID NO: 7
SEQ ID NO: 104 & SEQ ID NO: 7
SEQ ID NO: 105 & SEQ ID NO: 7
SEQ ID NO: 106 & SEQ ID NO: 171
SEQ ID NO: 106 & SEQ ID NO: 172
SEQ ID NO: 107 & SEQ ID NO: 171
SEQ ID NO: 107 & SEQ ID NO: 172
SEQ ID NO: 108 & SEQ ID NO: 171
SEQ ID NO: 108 & SEQ ID NO: 172
SEQ ID NO: 109 & SEQ ID NO: 170
SEQ ID NO: 110 & SEQ ID NO: 171
SEQ ID NO: 111 & SEQ ID NO: 172
SEQ ID NO: 112 & SEQ ID NO: 169
SEQ ID NO: 113 & SEQ ID NO: 173
SEQ ID NO: 113 & SEQ ID NO: 174
SEQ ID NO: 113 & SEQ ID NO: 175
SEQ ID NO: 113 & SEQ ID NO: 176
SEQ ID NO: 113 & SEQ ID NO: 177
SEQ ID NO: 113 & SEQ ID NO: 176
SEQ ID NO: 114 & SEQ ID NO: 173
SEQ ID NO: 114 & SEQ ID NO: 174
SEQ ID NO: 114 & SEQ ID NO: 175
SEQ ID NO: 114 & SEQ ID NO: 176
SEQ ID NO: 114 & SEQ ID NO: 177
SEQ ID NO: 115 & SEQ ID NO: 173
SEQ ID NO: 115 & SEQ ID NO: 174
SEQ ID NO: 115 & SEQ ID NO: 175
SEQ ID NO: 115 & SEQ ID NO: 176
SEQ ID NO: 115 & SEQ ID NO: 177
SEQ ID NO: 115 & SEQ ID NO: 181
SEQ ID NO: 115 & SEQ ID NO: 182
SEQ ID NO: 115 & SEQ ID NO: 183
SEQ ID NO: 115 & SEQ ID NO: 184
SEQ ID NO: 115 & SEQ ID NO: 185
SEQ ID NO: 115 & SEQ ID NO: 186
SEQ ID NO: 115 & SEQ ID NO: 187
SEQ ID NO: 115 & SEQ ID NO: 188
SEQ ID NO: 115 & SEQ ID NO: 189
SEQ ID NO: 115 & SEQ ID NO: 190
SEQ ID NO: 115 & SEQ ID NO: 192
SEQ ID NO: 115 & SEQ ID NO: 193
SEQ ID NO: 115 & SEQ ID NO: 194
SEQ ID NO: 115 & SEQ ID NO: 195
SEQ ID NO: 115 & SEQ ID NO: 196
SEQ ID NO: 115 & SEQ ID NO: 197
SEQ ID NO: 115 & SEQ ID NO: 198
SEQ ID NO: 115 & SEQ ID NO: 199
SEQ ID NO: 115 & SEQ ID NO: 200
SEQ ID NO: 115 & SEQ ID NO: 201
SEQ ID NO: 116 & SEQ ID NO: 173
SEQ ID NO: 116 & SEQ ID NO: 174
SEQ ID NO: 116 & SEQ ID NO: 175
SEQ ID NO: 116 & SEQ ID NO: 176
SEQ ID NO: 116 & SEQ ID NO: 177
SEQ ID NO: 117 & SEQ ID NO: 173
SEQ ID NO: 117 & SEQ ID NO: 174
SEQ ID NO: 117 & SEQ ID NO: 175
SEQ ID NO: 117 & SEQ ID NO: 176
SEQ ID NO: 117 & SEQ ID NO: 177
SEQ ID NO: 118 & SEQ ID NO: 178
SEQ ID NO: 118 & SEQ ID NO: 179
SEQ ID NO: 119 & SEQ ID NO: 178
SEQ ID NO: 119 & SEQ ID NO: 179
SEQ ID NO: 119 & SEQ ID NO: 51
SEQ ID NO: 119 & SEQ ID NO: 189
SEQ ID NO: 119 & SEQ ID NO: 46
SEQ ID NO: 119 & SEQ ID NO: 47
SEQ ID NO: 119 & SEQ ID NO: 48
SEQ ID NO: 119 & SEQ ID NO: 49
SEQ ID NO: 119 & SEQ ID NO: 50
SEQ ID NO: 119 & SEQ ID NO: 51
SEQ ID NO: 119 & SEQ ID NO: 52
SEQ ID NO: 120 & SEQ ID NO: 178
SEQ ID NO: 120 & SEQ ID NO: 179
SEQ ID NO: 122 & SEQ ID NO: 176
SEQ ID NO: 124 & SEQ ID NO: 176
SEQ ID NO: 125 & SEQ ID NO: 176
SEQ ID NO: 126 & SEQ ID NO: 176
SEQ ID NO: 127 & SEQ ID NO: 176
SEQ ID NO: 128 & SEQ ID NO: 176
SEQ ID NO: 129 & SEQ ID NO: 176
SEQ ID NO: 130 & SEQ ID NO: 176
SEQ ID NO: 131 & SEQ ID NO: 176
SEQ ID NO: 132 & SEQ ID NO: 176
SEQ ID NO: 133 & SEQ ID NO: 176
SEQ ID NO: 134 & SEQ ID NO: 176
SEQ ID NO: 135 & SEQ ID NO: 176
SEQ ID NO: 136 & SEQ ID NO: 176
SEQ ID NO: 137 & SEQ ID NO: 176
SEQ ID NO: 138 & SEQ ID NO: 176
SEQ ID NO: 139 & SEQ ID NO: 176
SEQ ID NO: 140 & SEQ ID NO: 176
SEQ ID NO: 141 & SEQ ID NO: 176
SEQ ID NO: 142 & SEQ ID NO: 176
SEQ ID NO: 143 & SEQ ID NO: 176
SEQ ID NO: 144 & SEQ ID NO: 176
SEQ ID NO: 145 & SEQ ID NO: 176
SEQ ID NO: 146 & SEQ ID NO: 176
SEQ ID NO: 147 & SEQ ID NO: 176
SEQ ID NO: 148 & SEQ ID NO: 176
SEQ ID NO: 149 & SEQ ID NO: 176
SEQ ID NO: 150 & SEQ ID NO: 176
SEQ ID NO: 151 & SEQ ID NO: 176
SEQ ID NO: 152 & SEQ ID NO: 176
SEQ ID NO: 153 & SEQ ID NO: 189
SEQ ID NO: 154 & SEQ ID NO: 189
SEQ ID NO: 155 & SEQ ID NO: 189
SEQ ID NO: 156 & SEQ ID NO: 189
SEQ ID NO: 157 & SEQ ID NO: 189
SEQ ID NO: 158 & SEQ ID NO: 189
SEQ ID NO: 159 & SEQ ID NO: 189
SEQ ID NO: 160 & SEQ ID NO: 189
SEQ ID NO: 161 & SEQ ID NO: 189
SEQ ID NO: 161 & SEQ ID NO: 179
SEQ ID NO: 162 & SEQ ID NO: 189
SEQ ID NO: 162 & SEQ ID NO: 179
SEQ ID NO: 163 & SEQ ID NO: 189
SEQ ID NO: 163 & SEQ ID NO: 179
SEQ ID NO: 164 & SEQ ID NO: 189
SEQ ID NO: 164 & SEQ ID NO: 179
SEQ ID NO: 165 & SEQ ID NO: 189
SEQ ID NO: 165 & SEQ ID NO: 179
SEQ ID NO: 166 & SEQ ID NO: 189
SEQ ID NO: 166 & SEQ ID NO: 179
SEQ ID NO: 167 & SEQ ID NO: 189
SEQ ID NO: 167 & SEQ ID NO: 179
SEQ ID NO: 168 & SEQ ID NO: 189
8 . An antibody as claimed in claim 1 in which the antibody comprises a human or non-human primate heavy chain immunoglobulin constant region selected from a group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgE and IgA
9 . An antibody as claimed in claim 1 in which the antibody comprises a human or non-human primate light chain immunoglobulin constant region selected from a group consisting of kappa or lambda.
10 . An antibody as claimed in claim 1 in which the antibody is modified by the covalent attachment of an organic moiety.
11 . An antibody as claimed in claim 10 in which the organic moiety is a linear or branched hydrophilic polymeric group, fatty acid group, or fatty acid ester group.
12 . An antibody as claimed in claim 1 in which the antibody is modified to modulate a functional characteristic selected from the group consisting of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, serum half-life, biodistribution and binding to Fc receptors.
13 . An antibody as claimed in claim 12 in which the modification is by protein engineering, glycoengineering or chemical methods.
14 . A nucleic acid molecule in which the nucleic acid encodes a VH domain as claimed in claim 1 .
15 . A nucleic acid molecule as claimed in claim 14 in which the nucleic acid has a sequence selected from:
SEQ ID NO: 217
SEQ ID NO: 218
SEQ ID NO: 219
SEQ ID NO: 220
SEQ ID NO: 222
SEQ ID NO: 223
SEQ ID NO: 224
SEQ ID NO: 225
SEQ ID NO: 227
SEQ ID NO: 228
SEQ ID NO: 229
SEQ ID NO: 230
SEQ ID NO: 232
SEQ ID NO: 233
SEQ ID NO: 234
SEQ ID NO: 242
SEQ ID NO: 243
SEQ ID NO: 244
SEQ ID NO: 245
SEQ ID NO: 246
SEQ ID NO: 247
SEQ ID NO: 248
SEQ ID NO: 249
SEQ ID NO: 250
SEQ ID NO: 251
SEQ ID NO: 252
SEQ ID NO: 254
SEQ ID NO: 255
SEQ ID NO: 257
SEQ ID NO: 258
SEQ ID NO: 259
SEQ ID NO: 260
SEQ ID NO: 261
SEQ ID NO: 262
SEQ ID NO: 263
SEQ ID NO: 264
SEQ ID NO: 266
SEQ ID NO: 267
SEQ ID NO: 268
SEQ ID NO: 269
SEQ ID NO: 270
SEQ ID NO: 271
SEQ ID NO: 272
SEQ ID NO: 273
SEQ ID NO: 274
SEQ ID NO: 275
SEQ ID NO: 276
SEQ ID NO: 277
SEQ ID NO: 278
SEQ ID NO: 279
SEQ ID NO: 280
SEQ ID NO: 281
SEQ ID NO: 282
SEQ ID NO: 283
SEQ ID NO: 284
SEQ ID NO: 285
SEQ ID NO: 286
SEQ ID NO: 287
SEQ ID NO: 289
SEQ ID NO: 291
SEQ ID NO: 292
SEQ ID NO: 293
SEQ ID NO: 294
SEQ ID NO: 295
SEQ ID NO: 296
SEQ ID NO: 297
SEQ ID NO: 298
SEQ ID NO: 299
SEQ ID NO: 300
SEQ ID NO: 301
SEQ ID NO: 302
SEQ ID NO: 303
SEQ ID NO: 304
SEQ ID NO: 305
SEQ ID NO: 306
SEQ ID NO: 307
SEQ ID NO: 308
SEQ ID NO: 309
SEQ ID NO: 310
SEQ ID NO: 311
SEQ ID NO: 312
SEQ ID NO: 313
SEQ ID NO: 314
SEQ ID NO: 315
SEQ ID NO: 316
SEQ ID NO: 317
SEQ ID NO: 318
SEQ ID NO: 319
SEQ ID NO: 320
SEQ ID NO: 321
SEQ ID NO: 322
SEQ ID NO: 323
SEQ ID NO: 324
SEQ ID NO: 325
SEQ ID NO: 326
SEQ ID NO: 327
SEQ ID NO: 328
SEQ ID NO: 329
SEQ ID NO: 330
SEQ ID NO: 331
SEQ ID NO: 332
SEQ ID NO: 333
SEQ ID NO: 334
SEQ ID NO: 335
16 . A nucleic acid molecule in which the nucleic acid encodes a VL domain as claimed in claim 1 .
17 . A nucleic acid molecule as claimed in claim 16 in which the nucleic acid has a sequence selected from:
SEQ ID NO: 221
SEQ ID NO: 226
SEQ ID NO: 231
SEQ ID NO: 235
SEQ ID NO: 236
SEQ ID NO: 237
SEQ ID NO: 238
SEQ ID NO: 239
SEQ ID NO: 240
SEQ ID NO: 241
SEQ ID NO: 336
SEQ ID NO: 338
SEQ ID NO: 339
SEQ ID NO: 340
SEQ ID NO: 341
SEQ ID NO: 342
SEQ ID NO: 343
SEQ ID NO: 344
SEQ ID NO: 345
SEQ ID NO: 346
SEQ ID NO: 347
SEQ ID NO: 348
SEQ ID NO: 350
SEQ ID NO: 351
SEQ ID NO: 352
SEQ ID NO: 353
SEQ ID NO: 354
SEQ ID NO: 355
SEQ ID NO: 356
SEQ ID NO: 357
SEQ ID NO: 358
SEQ ID NO: 359
SEQ ID NO: 361
SEQ ID NO: 362
SEQ ID NO: 363
SEQ ID NO: 364
SEQ ID NO: 365
SEQ ID NO: 366
SEQ ID NO: 367
SEQ ID NO: 368
SEQ ID NO: 369
SEQ ID NO: 370
18 . A method of treating a disease in a subject comprising administering to the subject an antibody as claimed in claim 1 wherein the disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, reactive arthritis, psoriatic arthritis, bone loss, airways hypersensitivity, chronic obstructive pulmonary disease, a demyelinating disorder, psoriasis, multiple sclerosis, dermal hypersensitivity, acute and chronic transplant rejection, allograft rejection, graft-versus host disease, systemic sclerosis, systemic lupus erythematosus, an autoimmune inflammatory bowel disease, a urological inflammatory disorder, a cardiovascular disease, a vasculitis, a periodic fever, a glucose metabolism disorder, a pulmonary disease, a cancer, peridontitis, hepatic stromal keratitis, an allergy, inflammatory pain, a spondyloarthropathy, septicaemia, septic or endotoxic shock, meningitis, surgical trauma, an autoimmune haematological disorder, Alzheimer's disease, sarcoidosis, cirrhosis, hepatitis (including autoimmune hepatitis), primary biliary cirrhosis, uveitis, thyroiditis, atherosclerosis, alopecia, Wilson's disease, glomerulonephritis and dislipidemia.Join the waitlist — get patent alerts
Track US2016264661A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.